Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 15, 2026 09:00 ET | Source: NewcelX Ltd.

NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio

ZURICH, July 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced that the...
July 08, 2026 09:15 ET | Source: NewcelX Ltd.

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials Dr. Ricordi to support advancement...
July 01, 2026 09:30 ET | Source: NewcelX Ltd.

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful...
June 15, 2026 08:30 ET | Source: NewcelX AG

NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform

Study published in Stem Cell Reports demonstrates that AstroRx® - a therapy derived from NewcelX’s platform - addresses key barriers to remyelination with potential to treat chronic demyelinating...
May 27, 2026 07:55 ET | Source: NewcelX Ltd.

NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”;...
April 30, 2026 08:15 ET | Source: NewcelX Ltd.

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key...
April 20, 2026 07:37 ET | Source: NewcelX Ltd.

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived...
April 01, 2026 07:21 ET | Source: NewcelX Ltd.

NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a...